← Back to headlines
Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns
Merck has finalized a deal worth nearly $6 billion to acquire Terns, a cancer biotech company, signaling a major acquisition in the pharmaceutical and biotechnology sector.
25 Mar, 13:14 — 25 Mar, 13:14
Sources
Showing 1 of 1 sources
